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Résumé Summary
Ce cas, basé sur des expériences personnelles ainsi que
sur celles trouvées dans la littérature, met en évidence la
tension délicate à laquelle sont confrontées les entreprises
vouées au développement des médicaments soit
d’équilibrer l’intégrité de la recherche et leur rentabilité. 
This case, based on personal experiences and on those
found in the literature, highlights the delicate tension faced
by drug development companies having to balance
research integrity and their profitability.
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Introduction 
The development of a new drug is a complex and daunting endeavour, and biotechnology companies
may find themselves torn between their financial interests and the interests of research participants. In
this paper, I present a case study that describes, from the perspective of a decision-maker within a
pharmaceutical company, the elements that can lead to having to choose, under commercial and
financial pressures, between the integrity of the conduct of drug development and the profitability of a
company. Such a dilemma may appear for some as simplistic – by watering down the complexity of
ethical decision-making processes – but is rather good at showcasing how a company must deal with
two core values (integrity versus profitability) to remain in business [1]. Corporate image and
commercial efficiency may not be at the core of the moral dilemma from a bioethical standpoint, and
research ethics might demand that the obvious primary responsibility, no matter the context, is above
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everything else the protection of participants [2]. However, from a pragmatic point of view,
sophisticated ethical issues may not be the primary focus of a set of actors with very different
concerns who are incentivized to voluntarily choose to disregard ethical imperative in favour of short-
term gains [3,4]. Based on what biotechnology firms are continuously facing to stay in business [5],
this case serves to highlight the importance of the pressure experienced by actors in competitive
commercial contexts [6,7] and enriches the discussions in bioethics about the ethical conduct of
companies [8-10].
The Case
The discovery of a promising new medication brings great joy and hope to many researchers, to
patients seeking effective treatment and, more broadly, to the business community and society. Most
experimental medications, however, never reach the market, and the commercialization of even the
most promising few is a long, arduous, and costly endeavour.
A small Canadian private biotechnology company BioMelior1 has succeeded in developing a
promising molecule (BioM-8902) demonstrating a reversing effect on Alzheimer’s disease. The drug
would represent the first drug to prevent the symptoms from getting worse and to show a moderate
improvement over time. As the demand for Alzheimer’s treatments is high in wealthier countries, the
population is expected to be large enough for the drug to be profitable and the therapeutic offer (i.e.,
competition) is still limited. BioM-890 has recently been patented and the company was able to obtain
funding from venture capital (VC)3 to further push the development of the product. However, the
company’s resources are limited, the financial risk remains very high and commercialization is still far
off and uncertain. As with any drug development, BioMelior needs to take the following steps: conduct
preclinical trials (laboratory and animal testing) and the three clinical trial phases on humans in order
to collect the necessary data to request approval by Health Canada [11].
Due to the limitations of BioMelior’s human, material and infrastructural resources, management
decided to deal with a contract research organization (CRO). Considering that the clinical trials are the
most expensive aspect of drug development [12], outsourcing is a common practice in the industry as
a means of significantly reducing costs [13,14]. The Indian-owned CRO AlphaLab4 was identified for
preclinical trials since it excels in conducting such research, and a service offer was commissioned. In
the details of the offer, AlphaLab proposed to add provisions for the conduct of phase I to III clinical
trials if the molecule is compliant (safe and efficient) enough to continue development (see Figure 1,
option 1). AlphaLab offers a considerable price reduction compared to the market price of conducting
clinical trials with human participants and faster deliverables for a complete package, including
preclinical and clinical phases.
This offer represents a very advantageous solution considering BioMelior’s limited resources, as it
would reduce the financial risk for both the company and its VC partners. Although the decision rests
with upper management of the company, pressure by the partners is strong to sign an exclusive
contract with AlphaLab. However, while effective and recognized in preclinical research, AlphaLab
does not have a very good reputation for tests with human participants. In recent years, the CRO
faced allegations from some media for unethical participant recruitment in Asia, as the CRO conducts
these trials largely in India and China. Even if presumed compliant with international standards for
good clinical trials, AlphaLab works with local subcontractors which might raise a number of ethical
concerns: the CRO will only remotely oversee the conduct of research and BioMelior will have no
control over the selection of local subcontractors whose conduct and reputation may not be
1 BioMelior is a fictional company.
2 BioM-890 is a fictional molecule.
3 Venture capital is a type of investment in the early-stage of a company or a product when profitability is uncertain. It is also
referred to as “risk capital”.
4 AlphaLab is a fictional company.
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advantageous considering that they may have a “flexible” definition of what constitutes an ethical trial.
That being said, in the last few months AlphaLab has changed ownership and the new administration
revamped their standard operating procedures. In light of this transition, some experts see the
changes as promising signs, but this does not constitute a strong guarantee.
To get a better idea of the options and to assess the potential savings achieved by doing business
with AlphaLab, BioMelior’s leaders seek other CROs working particularly in phases I to III (See Figure
1, option 2). Of the proposals, only one stands out. Nearly three times more expensive than
AlphaLab’s tender, the Canadian-based CRO BetaLab5 performs all its trials in Canada, even if this is
not a requirement under Canadian regulation, following the Tri-Council Policy Statement: Ethical
Conduct for Research Involving Humans (TCPS2)6 as well as ICH’s Good Clinical Practice7. The price
comes with, among other things, the insurance of high medical standards, constant monitoring of the
participants, and appropriate informed consent. BetaLab has a very good reputation with a long
history of collaboration with Canadian health care institutions.
Figure 1 – Options for the Conduct of Drug Development Phases
There are two options for the conduct of drug development phases. Option 1 provides an exclusive contract to
the firm AlphaLab and thus can generate big savings. Option 2 maintains the preclinical phase with AlphaLab,
but all further phases involving human subjects will be conducted with BetaLab. 
The Decision
Given the importance for BioM-890’s development potential and, more broadly, the BioMelior’s
financial future and the welfare of participants, concerns about which CRO to choose were raised at a
meeting of the company Board of Directors (the Board). From the beginning of the session, it
becomes clear that the CRO choice is a source of great tension among the administrators. Some hold
the opinion that the decision should focus on which CRO is the most capable of running compliant
clinical trials, while others are more concerned about costs and profitability.
5 BetaLab is a fictional company.
6 The TCPS, revised in 2014, is the leading document in research ethics in Canada. It is only required for studies conducted
with funds from Canadian granting councils, which would not normally be the case for a biotechnology company like
BioMelior. For more information, see [15].
7 The International Conference on Harmonisation (ICH) sets the international standards applying to clinical trials on human
subjects, called Good Clinical Practices (GCP). For more information, see [16].
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During the discussion, two board members argue for diametrically opposed considerations which
have great influence on all other members. On the one hand, Ms. Smith, a former member of a private
Research Ethics Board (REB), argues about the importance of reputation, responsibility for the
respect of participants, the financial risks, and the associated delays of a research protocol rejection
by the private REB contracted by BioMelior. According to Ms. Smith, BetaLab is offering more control
over the trials and respecting the highest standards in the conduct of tests. Thus, choosing Betalab
would minimize the risks arising from sloppy trials, thereby better serving BioMelior’s commercial
interests in addition to complying with the strict requirements of Canadian regulations and REB
standards. She claims that Option 2 is the only viable solution. On the other hand, Mr. Taylor, a
member representing VC partners, threatens to withdraw VC investment if BioMelior deals with
BetaLab, the most expensive CRO, as they charge three-time more than AlphaLab for phase I to III.
He indicates that it is better to opt for the solution that will ensure the development and profitability of
BioM-890, so Option 1 must be chosen. In his experience, only 11% of molecules reach the
market [17], so it would not be to the advantage of the company nor patients if the development of this
promising drug was stopped for lack of funding. Furthermore, he indicates that the change of
ownership is a good sign and that the CRO AlphaLab, being bound by contract, is solely responsible
for its actions and contingent misconduct.
As a Board member, you must decide between the proposal of AlphaLab or BetaLab for conducting
phases I to III. The future of the product (and, to some extent, of the company) may depend on this
decision (see Figure 2). On the one hand, the product, expected to be a breakthrough in a promising
market, could relieve patients and provide them with a solution for their nearly untreated condition. On
the other hand, the company’s financial resources are limited and the VC partners’ threat of
withdrawing their funding if the product development costs exceed what was initially budgeted. This
threat is real and could mean the end of BioM-890 development. Still, flaws in research integrity could
also be very harmful for the development and approval processes, and could even risk leading to a
scandal when the product is marketed.
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Figure 2 – Decision-making Process within BioMelior’s Organizational Chart
As a member of the Board, you have to decide between the two options as per Mr. Taylor’s and Ms. Smith’s 
suggestions.
Reasoning: Between Integrity and Innovation 
Actors and influences
• The situation has several actors who each have a different influence on the situation and have
their own interests.
o How many different actors do you identify? How many different “interests” are there?
o What are the competing interests of one or more actors? What are the converging
interests of one or more actors?
o Are there any conflicts of interests? And if so, for whom?
o Who is the dominant actor? Are its interests overruling others? Does this affect (or
should it affect) the decisions of the other actors?
Integrity and Research Ethics
• Ms. Smith argues that reputation and responsibility are important dimensions of drug
development.
o Does the fact that clinical trial’s local decision-making is made by a third party rather
than directly by BioMelior’s headquarters (due to the outsourcing of the clinical trial)
have a negative impact on the image and accountability of the company? Why?
o Does outsourcing to a CRO reduce BioMelior’s responsibility because another entity
manages the clinical trials?
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o Who is ultimately responsible for ensuring that the ethical standards are followed? Or is
it a shared responsibility, and if so, between whom?
• The development of BioM-890 is conducted completely in the private sector, without any
collaboration with university researchers or the major public granting councils. Therefore, the
Tri-Council Policy Statement (TCPS2), the Canadian flagship research ethics document, does
not apply.
o Does the fact that the company is dealing with a private REB have an influence on the
ethical review of its clinical trials? What kind of influences might be at stake?
o Are the integrity of the drug development process and the ethical conduct of clinical
trials with humans compromised by the fact that respect for the TCPS2 is not required?
o Is this situation desirable? What would be the best solution to ensure an efficient
ethical evaluation of such clinical trials?
Innovation and Business Ethics 
• The argument of Mr. Taylor suggests that the financial risks (e.g., expenditures incurred, delay
in development and in the marketing of the product) are too important, and thus there is an
imperative to sign with AlphaLab to protect the product’s profitability.
o Who would assume most of the risks? The research participants or the venture capital
investors?
 Corollary: Are the risks taken by VC investors being inappropriately transferred
to research participants?
o Is the power of the funders (exemplified by the statements and actions of Mr. Taylor)
too great? Is it limiting the decisional independence of the Board?
• How should one weigh the importance of developing a promising drug compared to the ethical
pitfalls associated with the approval and commercialization of the product?
o Is it possible, and if so how, to prioritize between integrity and profitability?
o Is it justifiable to conduct research without decent integrity assurance if the expected
outcomes for the patients are greater than the risks for the research participants?
o Does this influence innovation possibilities and commercial development? Is it
desirable?
The Verdict 
• Under the conditions presented in this case, for which CRO would you vote as a member of
the Board of Directors? What are the values and interests guiding your decision?
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